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Summary 
Surface modification of living cells with natural or synthetic polymers is a powerful and 
useful tool in biomedical studies.  Various functional groups and bioactive substances 
can be immobilized to the cell surface through covalent conjugation, electrostatic 
interaction, or hydrophobic interaction.  In this review, we provide an overview of the 
methods and polymers employed in cell surface modification, including: (1) covalent 
conjugation utilizing amino groups of cell surface proteins, (2) electrostatic interaction 
between cationic polymers and a negatively charged cell surface, and (3) hydrophobic 
interaction of amphiphilic polymers with the lipid bilayer membrane.  We also discuss 
their applications in studies on cell transplantation, cell-cell interaction analysis, cell 
arrangement, and lineage determination of stem cells. 
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1. Introduction 
Surface modification of living cells with natural and synthetic polymers allows for new 
opportunities in biomedical engineering and science.  A variety of functional groups 
and bioactive substances have been introduced onto the cell surface.  The three methods 
generally employed in cell surface modification are covalent conjugation, electrostatic 
interaction, and hydrophobic interaction.  
 In this review, we provide an overview of the methods and polymers employed 
in cell surface modification in conjunction with their applications in biomedical 
engineering and science;  applications discussed include: (1) adding biological functions, 
such as blood compatibility, to the cell surface, (2) controlling graft rejection in cell 
transplantation by masking surface antigens of cells with natural or synthetic polymers, 
and (3) aligning different kinds of cells through interactions between complementary 
units, such as oligoT and oligoA, introduced on different cell surfaces.  Cell surface 
modification, still an emergent research area, can be used to study cell-cell interaction 
and to control stem cell lineages in regenerative medicine.  It is anticipated cell surface 
modification technology will soon be applied to the treatment of patients in the areas of 
regenerative medicine, tissue engineering, stem cell research, and embryology. 
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2. Methods for cell surface modification 
Surface modification of cells has been generally achieved through three methods: (1) 
covalent conjugation to amino groups of cell surface proteins, (2) electrostatic 
interaction between cationic polymers and a negatively charged surface, and (3) 
incorporation of amphiphilic polymers into the lipid bilayer membrane of cells by 
hydrophobic interaction.  The methods are summarized in Fig. 1.  Attempts have been 
made with various kinds of synthetic and natural polymers for surface modification of 
cells and biomaterials.
1,2
 Poly(ethylene glycol) (PEG) is currently considered a suitable, 
biocompatible material for surface modification;  PEG is a hydrated, flexible polymer 
chain (Fig. 1a), which works as a steric barrier on the cell surface. 
 
2.1. Covalent bond method 
For covalent conjugation of polymers, surface modification of living cells has been 
achieved through chemical or enzymatic treatment or by metabolic introduction.
3-11
 As 
shown in Fig. 1b, the N-hydroxyl-succinimidyl ester (NHS) group and cyanuric chloride 
are generally used to chemically form covalent amide bonds to membrane proteins.
7-11
 
These groups mainly react with amino groups of protein; however, there is a potential 
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for denaturation membrane proteins or be cytotoxic due to the chemical modification of 
membrane and cytoplasmic proteins.
 3,4
 
Enzymatic treatment and metabolic introduction have been applied to cell lines to add 
various molecules such as biotin, azide, and ketone groups to living cell surfaces.
3-6
 The 
introduction of these molecules enables cells to gain new biological functions.  
However, these procedures are difficult to apply to primary cells in culture or cells to be 
transplanted, such as islets.  In addition, the technologies are limited to the introduction 
of specified functional small molecules to specified cells and might perturb cell 
physiology.
5,6
 Finally, although covalent immobilization was expected to be stable for 
chemical degradation and present for a long time because of covalent bonding to 




2.2. Hydrophobic interaction-based cell surface modification using amphiphilic 
polymers 
Amphiphilic polymers such as PEG-conjugated phospholipids (PEG-lipid) and 
poly(vinyl alcohol) bearing alkyl side chains (PVA-alkyl), have been used for cell 
surface modification as a noncovalent cell surface modification technique (Fig. 1c).
5,6,12-
18
 In this method, amphiphilc polymers are simultaneously introduced into the lipid 
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bilayer membranes by hydrophobic interactions, without cytotoxicity.  This surface 
modification does not cause protein denaturation or affect cell function.  PEG-lipid has 
been widely used for the surface modification of liposomes.
19,20
 Surface modification 
with PEG-lipid prolongs circulation time in vivo and improves biocompatibility.  PEG-
lipid is an amphiphilic molecule which is composed of a hydrophilic PEG chain and 
hydrophobic phospholipid.  The PEG chain can be anchored to the cell surface because 
the hydrophobic part of PEG-lipid is spontaneously incorporated into the lipid bilayer 
membrane when PEG-lipid is mixed with cells (Fig. 2a).  It is possible to form the PEG 
layer at a several nanometer level on the cell surface, depending on the molecular 
weight of PEG.  This spontaneous incorporation can be monitored by a surface plasmon 
resonance (SPR) instrument when PEG-lipid solution is applied onto the supported lipid 
membrane (Fig. 2b).  Small unilamellar vesicles are applied to methyl-terminated self-
assemble monolayer (SAM) surfaces to form the supported lipid membrane.  Then, 
PEG-lipid solution is applied and the incorporation into the membrane is monitored.  
The spontaneous incorporation of PEG-lipid can be observed and it is greatly affected 
by the hydrophobicity of the phospholipid.  
To demonstrate the surface modification of cells with PEG-lipid, CCRF-CEM (Human 
cell line derived from T cell leukemia) floating cells were used.  FITC was conjugated 
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to the end of the PEG chain of PEG-lipid for fluorescence labeling.  Cells were 
incubated in FITC-PEG-lipid solution for 30 min at room temperature.  After washing 
with PBS, treated cells were observed with a confocal laser scanning microscope (Fig. 
2c).  The fluorescence of FITC was observed at the periphery of all cells, indicating 
PEG-lipids were anchoring to the lipid bilayer membrane of cell surfaces by 
hydrophobic interaction.  PEG-lipids were gradually disappeared from the cell surface 
without uptake into the inside of cells. They were dissociated from cell surface into 
medium as seen in Fig. 2(b). Cell viability was assessed by the trypan blue exclusion 
method.  There was no cytotoxicity in cells treated with FITC-PEG-lipid as PEG is 
biocompatible and phospholipids are components of cell membranes.  This method can 
also be applied to the surface modification of adherent HEK293 cells with PEG-lipid.  
Another type of amphiphilic PVA derivative carrying long alkyl side chains can be also 
used for surface modification, allowing interactions with the cell membrane at multiple 
points.  It was observed that PVA-alkyls gathered at an area on the membrane, similar 





2.3. Electrostatic interaction 
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Several groups have explored the possibility of constructing thin polymer membranes 
on the surface of cells or islets using layer-by-layer of anionic and cationic polymers 
such as poly(allylamine hydrochloride) (PAH), poly(styrene) sulfate (PSS), poly-L-
lysine (PLL), and poly(ethyleneimine) (PEI), as shown in Fig. 1d and e.
21-25
 Cationic 
polymers interact with negatively charged cell surfaces and anionic polymers are treated 
to form layer-by-layer membranes as the procedure is repeated.  However, most 
polycations were found to be extremely cytotoxic and severely damaged treated cells.  
When cells were mixed with PEI solution, PEI exerted an immediate toxic effect on 
cells
14
 by strongly interacting with the cell, destroying the cell membrane, and invading 
the cells by simple incubation.  No clear change in PEI was seen on dead cells over 2 
days. PEI which interacted with cell was not degraded and not excluded from the cell 
because PEI immediately destroyed the cell membrane after interaction with cell surface. 
In contrast, no bright ring or spots were observed on/in cells exposed to the FITC-
labeled anionic polymers.  The polyanions did not adsorb on the cell surface or exert 
toxic effects on the cells.  
 
2.4. Layer-by-layer method 
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A layer-by-layer method is a simple method to form a thin polymer membrane on the 
cell surface.
26
 The surface property can be controlled by the outermost layer of polymer.  
The thickness of the membrane is also controllable by the number of applications of 
polymer solution.  The technique is used for the surface modification of living cells.  In 
most cases, the formation of layer-by-layer membranes of polymers can be achieved 
through polyion complexes using polycation and polyanion (Fig. 1e).  Polycations, such 
as PAH, PLL, and PEI, are often used as interactive polymers with the cell surface; 
although, they are cytotoxic.  Alginate and PSS and are widely used as polyanions.  
Several groups have recently tried to construct thin membranes on the surface of cells 
by the layer-by-layer method.
21-25
 Cell viability was extremely decreased due to the 
cytotoxicity of the polycations although they succeeded in forming polyelectrolyte 
multilayer membranes on cell surfaces.  
We tried to assemble polymers by disulfide bonding on the cell surface without polyion 
complex.
12
 A thiol/disulfide exchange reaction between a thiol group and a pyridyl 
disulfide (PD) group can be used to form a multilayered polymer membrane on the 
surface.  The thiol group is expected to react efficiently with the PD group to form a 
disulfide bond before autoxidation of the thiol group proceeds.  The thiol/disulfide 
exchange reaction is a mild reaction suitable for the formation of a multilayered 
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polymer membrane, without damaging the living cell surface.  When the surface was 
treated alternatively with poly(vinyl alcohol) (PVA) carrying a thiol group (PVA-SH) 
and PVA-PD, the multilayer of PVA was constructed (Fig. 1e). Since there is no 
interaction between those polymers and cell surface, the morphology of islets was 
maintained after surface modification. From a static glucose stimulation test, PVA-
encapsulated islets released insulin in response to glucose concentration changes, 
indicating that PVA encapsulation did not impair the insulin-secreting ability of islets.
12
 
Thus layer-by-layer method without use of polyion complex is promising because most 
polycations exert cytotoxicity.   
 
2.5. Bioactive substances immobilized through a intermediary molecule 
 The immobilization methods of bioactive substances are summarized in Fig. 1g.  
There are two classifications of this method.  One is immobilization of substances 
through an intermediary molecule which is covalently bound to membrane proteins on 
the surface via amide bonding with hetero- or homo-bifunctional cross-linkers.  In one 
example, biotin molecules are covalently bound to the amino groups of membrane 
proteins via cross-linkers.  The surface was then treated with avidin and heparin was 
immobilized to the surface through an electrostatic interaction with avidin (Isoelectric 
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point of avidin; pI=10).
9
 Phosphine molecules have also been covalently conjugated to 
amino groups of membrane proteins to immobilize recombinant thrombomodulin by 
Staudinger ligation.
10
 The immobilization of serum albumins has been attempted using 
PEG carrying NHS groups at both ends; one NHS is used for anchoring to the amino 
group of membrane proteins and the other for the immobilization of serum albumin.
11
 




The other method is formation of an intermediary polymer layer through hydrophobic 
interaction using amphiphilic polymers such as PEG-lipid and PVA-alkyl carrying 
various functional groups.
15,16
 The functional groups introduced through the 
amphiphilic polymers can be used for immobilization of bioactive substances.  In one 
example, PVA-alkyl carrying SH groups is used for immobilization of bioactive 
substances carrying maleimide groups. By the same means, PEG-lipid carrying 
maleimide at the end of the PEG chain is also useful for immobilization of bioactive 
substances carrying SH groups. There is no cytotoxicity after immobilization of proteins 
to the cell surface. 
 
3. Addition of supplementary functions on cell surfaces 
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Recently, cell surface modification has focused on adding supplementary biological 
function through cell transplantation, especially islet transplantation for improvement of 
graft survival.  In clinical islet transplantation, islets are transfused into the liver through 
the portal vein.
57,58
 The islets are lost in the early phase following transplantation, 
before immune-rejection reaction.  The blood coagulation and complement systems are 
activated by islets and chemotactic factors, tissue factor, chemokines, collagen, and 
other inflammatory mediators are released during the early post-transplantation phase.  
An immediate blood mediated inflammatory reaction (IBMIR) is activated, resulting in 
destruction of the transplanted islets.
27-32
 About 50% of islets are lost within an hour 
after transplantation into liver.
33





 low molecular weight dextran sulfate,
30
 and the water-soluble 
domain of complement receptor I (sCR1) have been systematically administered to 
regulate early coagulation and blood-mediated inflammatory reactions,
31,32
 resulting in a 
reduction of islets lost.  It is difficult, however, to apply these methods in the clinical 
setting because systemic administration is associated with an increased risk of bleeding.  
This issue can be avoided by the immobilization of substances having anticoagulant 
activities to the cell surface for improvement of biocompatibility. 
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3.1.  Immobilization of heparin on islets 
The effects of bioactive substances can be localized by the immobilization of such 
substances on the surface of islets.
9,10,15,16
 Nilsson et al.
 9
 proposed coating porcine islets 
with heparin to inhibit surface thrombosis formation (Fig. 3b).  Biotin was covalently 
immobilized on the surface of porcine islets using activated ester chemistry and the 
surfaces were further treated with avidin.  The islet surface was coated with 
macromolecular conjugates of heparin, ~70 heparin molecules covalently linked to an 
inert carrier chain.  In allotransplantation in pigs, increases in plasma concentrations of 
thrombin-antithrombin (TAT) complexes and complement activation parameter (C3a) 
were suppressed for heparin-coated islets compared with naïve islets.  The transient 
increase of insulin released from destroyed porcine islets was also suppressed.  These 
results suggest heparinization of the islet surface helps prevent IBMIR.  
 
3.2.  Proteins immobilized on islets 
Chaikof et al.
 10
 reported covalently immobilizing recombinant thrombomodulin to the 
surface of islets. Phosphine molecules were covalently conjugated to amino groups of 
membrane proteins to anchor recombinant thrombomodulin by Staudinger ligation.  The 
presence of thrombomodulin on the islet surface resulted in a significant increase in the 
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production of activated protein C with a reduction in islet-mediated thrombogenicity.  
Covalent immobilization of bioactive substances through membrane proteins is thought 
to deteriorate membrane protein functions and to perturb cell physiology.
3,4
 Our group 
developed non-covalent methods for surface modification of islets using various 
amphiphilic polymers such as PEG-conjugated phospholipid (PEG-lipid) and poly(vinyl 
alcohol) carrying alkyl chains.
12-18
 Fig. 5b depicts FITC-PEG-lipid modified hamster 
islets, observed by a confocal laser scanning microscope.  Islets are composed of a few 
thousand cells.  Clear fluorescence is seen at the periphery of each islet, indicating the 
outer cell layer was modified with PEG-lipid, forming a PEG layer on the islet.  This 
method was applied to non-covalently immobilize the fibrinolytic enzyme, urokinase, 
on the islet surface, as is schematically shown in Fig. 3.
16
 An amphiphilic PVA 
derivative carrying long alkyl side chains, thiol, and carboxylic groups was used for 
immobilization of urokinase on the islet surface.  Thiol groups were introduced to the 
islets surface using amphiphilic PVA derivatives through the hydrophobic interaction 
between the long alkyl side chains and lipid bilayer of the cell membrane (Fig. 3a).  
Urokinase was modified with a hetero-bifunctional cross-linker (sulfo-EMCS, N-(6-
Maleimidocaproyloxy) sulfosuccinimide) to introduce maleimide groups.  The 
urokinase carrying maleimide groups was immobilized to the islet surface through the 
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maleimide/thiol reaction.  Fig. 3b shows results from the fibrin plate-based assay.  
Urokinase is a serine protease that activates plasminogen to plasmin, which can dissolve 
fibrin gel.  To assess the fibrinolytic activity of the urokinase, urokinase-islets and naive 
islets (100 islets each) were spotted on a fibrin gel plate and left for 24 hours.  The 
transparent area formed in the fibrin, representing dissolved fibrin, was measured.  A 
large transparent area (diameter; 1.8 cm) was observed around the islets carrying 
urokinase, indicating urokinase activity.  The transparent area was small around naïve 
islet spots.  These results suggest immobilization of bioactive substances to the surface 
of islets is promising and a possible means for improving graft survival following intra 
portal transplantation. 
 
4. Masking of cell surface antigens 
 When an organ or tissue (the graft) from a donor is transplanted to a patient, the 
immune system of the patient recognizes the graft as foreign material and attacks and 
destroys it.  In allotransplantion, T cells are activated by recognition of antigens 
displayed on the surface of the graft.  The process initiates the adaptive immune 
response.  In xenotransplantation, hyperacute rejection is induced by pre-existing 
antibodies to the donor, resulting in a complement-mediated response in recipients.  The 
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graft is not accepted by the body of the transplant recipient.  Masking of the antigens of 
the graft has been examined to block the immune response to the graft.  In this section, 
we will present some examples where graft functioning periods were prolonged by 
masking antigens with synthetic polymers.  
 
4.1. Blood cells 
Surface modification with ultra thin polymer membranes was originally examined in red 
blood cells (RBC), chemically treated to enclose surface antigens.
35-39
 Camouflaging 
surface antigens is used to make universal RBC.  Methoxy(polyethylene glycol) 
(mPEG) was covalently bound to the surface of RBC via cyanuric chloride coupling.  
The reaction site of mPEG was accessible to the amino groups of lysine residues on 
membrane proteins.  The surface modification of RBC with mPEG was shown to 
prevent host antibodies from recognizing blood group surface antigens.
35-37
 It was also 
possible to prevent receptor–ligand interactions by conjugation of mPEG to the surface 
of human peripheral blood mononuclear cells
38
 and murine splenocytes.
39
 These 
receptor–ligand interactions involved allorecognition, including weakening CD28-B7 
co-stimulation which resulted in T cell apoptosis.  
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4.2. Bioartificial pancreas 
The masking of cell surface antigens has been extensively studied in islet 
transplantation and served as the basis for development of a bioartificial pancreas.  The 
concept of a bioartificial pancreas is shown in Fig. 4a.  An islet is encapsulated within a 
semi-permeable membrane.  The membrane masks the surface antigens of the islets  
from the recipient’s immune system.  Oxygen and nutrients are supplied through the 
membrane.  Insulin, secreted from islets in response to blood glucose increases, can 
diffuse into the recipient blood circulation through the membrane.  It is possible that 
transplanted islets can survive in the recipient without immuno-suppressive therapy and 
insulin release from the islets can control glucose metabolism for a long period.  The 
bioartificial pancreas has been studied for over 30 years.
40
 There have been three kinds 
of bioartificial pancreases including: a diffusion chamber type, hollow fiber type, and 
microcapsule type.
41-48
 We have found serious problems with the first two types.  Islets 
form large aggregates in chamber and hollow fiber type pancreases.  Also, many cells 
located in the central part of islets are lost due to an insufficient oxygen supply.  To 
prevent this, islets were enclosed within alginate hydrogel and transferred into the 
device to inhibit contact with each other.  In such trials, the size of the device became 
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too large to be implanted.  Efforts over the past 10 years have focused on the 
development of the microcapsule type.   
 
4.2.1. Microencapsulation of islets into hydrogel 
Our group developed a microcapsule type bioartificial pancreas using agarose hydrogel, 
as shown in Fig. 4b.  Hyperglycemia in diabetic mice could be normalized for 200 days 
after allotransplantation of agarose-encapsulated islets.
49-55
 Yet, the volume of the 
bioartificial pancreas still restricts its clinical applications.  The average diameter of 
islets is around 150 m.  The diameter of capsules is about three times as large as the 
original islets.  According to an estimate, the total volume of the microcapsules would 
be 27 times as large as that of the islets by a 3rd power increase of the radius.  In the 
human clinical setting, 10 mL of islet suspension would be infused into the portal vein.  
The volume of the capsule suspension would be greater than 270 mL and would need to 
be infused into the liver.  We would expect difficulties in infusion of microencapsulated 
islets into liver through the portal vein or its implantation in other transplantation sites 
in our body.  
Many studies have tried to reduce the size of capsules.  Calafiore et al.
 56
 reported much 
smaller microcapsules, i.e. 300 m diameter, which would provide a manageable total 
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volume for clinical applications.  However, the capsules with larger diameters than the 
islet itself are expected to plug larger blood vessels, imposing harmful effects on the 
patient’s liver.  The diameter of encapsulated islets must be much smaller to allow 
transplantation of the islets through portal veins.  Thus, new methods for the 
microencapsulation of islets, without increasing the diameter of the implant are 
necessary.  
 
4.2.2. Masking the surface antigens of islets with synthetic polymers  
The concept of the bioartificial pancreas was to cover the cell surface with polymer 
chains or thin membranes to mask the surface antigens (Fig. 5b-d).  Several groups 
originally proposed thin polymer membranes for coverage of the surface of cells and 
islets, such a PEG molecular and a layer-by-layer membranes of polymers.
12,13,15,21
 
Through proper control of PEG chain length and surface grafting density, the cell 
surface modification with PEG has been shown to camouflage antigenic sites, alter 
surface charge, and attenuate cell-cell and receptor-ligand interactions.
35-39
 Cationic 
polymers interact with the negatively charged cell surface and anionic polymers interact 
with the cationic polymer to form a layer-by-layer membrane by repeated sequential 
exposure of islet surface to cationic and anionic polymers.  
 - 20 - 
The activated ester group, N-hydroxyl-succinimidyl ester (NHS) group, at the end of 
PEG (PEG-NHS) has been employed to cover the surface antigen with a PEG layer.  It 
was reacted with the membrane proteins or collagen layer on the islets surface, as in 
mPEG-RBC.
38
 Byun et al. 
7,8  
reported covering the surface of islets with PEG, which 
reacted with the amino groups of the collagen layer remaining on the islet surface.  
Islets (1200) from a Sprague-Dawley rat were transplanted under the kidney capsule of 
streptozotocin (STZ)-induced diabetic Fisher 344 rats. When naked islets were 
transplanted without cyclosporine A, an immunosuppressive drug, normoglycemia 
could not be maintained for more than 5 days.  With low doses of cyclosporine A, 
normoglycemia could be prolonged for up to 12 days.  When the surface of islets was 
modified with PEG-NHS along with a low dose of cyclosporine A, normoglycemia 
could be maintained for 1 year.  It appeared rejection by the host immune system could 
be effectively suppressed with a combination of PEG and cyclosporine A.  Contreras et 
al. 
11 
applied the PEG-NHS modification method to xenogeneic transplantation.  There 
was no change in the morphology of porcine islets and viability after chemical 
modification with PEG. NHS-PEG-modified porcine islets were transplanted into the 
liver through the portal vein of NOD-SCID mice.  These mice were previously 
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 attempted to encapsulate human pancreatic islets by the layer-by-layer 
method and found there was minimal loss of islet function and viability when they were 
coated with a poly(allylamine hydrochloride) (PAH)/poly(styrene) sulfate (PSS)/PAH 
multilayer membrane. However, most cationic polymers, such as poly-L-lysine (PLL) 
and poly(ethyleneimine), were extremely cytotoxic and severely damaged treated cells.  
Although a layer-by-layer membrane could be formed on the islet surface using cationic 
and anionic polyelectrolytes, it was found that direct interaction between the cationic 
polymer and the cell surface should be avoided or the cell membrane would gradually 
be destroyed.  
Amphiphilic polymers, such as PEG-conjugated phospholipid (PEG-lipid) and 
poly(vinyl alcohol) carrying alkyl chains, have also been used to mask the surface 
antigens of islets.
12-18
 Although a confomal PEG layer formed on the cells or islet 
surface at nanometer levels of thickness (Fig. 5), the PEG layer disappeared from the 
cell surface approximately 3 days after FACS analysis.
14
 A more stable membrane 
should be employed for immuno-isolation.  To enclosure the whole surface with a stable 
membrane, a layer-by-layer membrane or a protein layer is further formed on the PEG-
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lipid modified cell surface.  Various functional groups, such as maleimide and biotin, 
are introduced to the end of the PEG chain to be used as reaction points for formation of 
a layer-by-layer membrane on the cell surface.  For example, it is possible to form a 
layer-by-layer membrane of poly(vinyl alcohol) (PVA) on the islets surface by the 
reaction between the thiol and maleimide groups.
12
 The islets carrying PEG-lipid- 
maleimide are exposed to a solution of PVA carrying thiol groups (PVA-SH) (Fig. 1e).  
A maleimide group reacts with a thiol group to form a stable covalent bond under 
physiological conditions.  A thiol/disulfide exchange reaction between a pyridyldithio 
group and thiol group can form a third layer on the islets, as shown in Fig. 4c. 
A multi-layer membrane can be also formed using a biotin-streptavidin reaction.  In our 
experiments, PEG-lipids carrying biotin at one end of PEG were applied to islets and 
anchored to the cell membranes.  The PEG-lipid layer on the islets was further covered 
by streptavidin and sequentially treated with bovine serum albumin carrying biotin.  
This procedure was repeated 20 times (Fig. 5d).
15
 The thickness of the membrane was 
about 30 nm, based on the calculation from surface plasmon resonance (SPR) analysis.  
A glucose stimulation test was performed to examine the ability of the modified islets to 
control insulin release in response to glucose level changes.  No significant differences 
in insulin release were observed between groups of islets with/without surface 
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modifications.  We also examined the effect of PEG modification on graft survival 
when islets were transplanted into the liver through the portal vein of STZ-induced 
diabetic mice.
18
 We found graft survival was improved by surface modification with 
PEG-lipid and cell damage to islets could be suppressed. 
Our group also examined coating the islet surface with an alginate/PLL/alginate 
multilayer, where NH2-PEG-lipid was introduced into islet cell membranes to form a 
positively charged islet surface to facilitate electrostatic binding of negatively charged 
alginate.
13
 The negatively charged surface was sequentially covered with PLL and 
alginate.  Islets coated with this membrane responded normally in a static glucose 
stimulation assay. 
 
5. Arrangement of different kinds of cells 
There are various applications of PEG-lipid derivatives in cell biology.  For example, 
when PEG-lipids carrying biotin or oligoDNA sequences are used for cell surface 
modification, different kinds of cells can be attached or alternatively aligned by specific 
interactions or hybridization of PEG-lipid derivatives on the surface. 
 
5.1. Alignment of single cells 
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Figure 6 shows an example of cell-cell attachment on the cell surface, induced by 
hybridization of oligoDNA at the end of PEG-lipid.  The sequences of oligoDNA were: 
polyA20: 5’-AAA AAA AAA AAA AAA AAA AA-3’ 
polyT20: 5’-TTT TTT TTT TTT TTT TTT TT-3’ 
PolyA20-PEG-lipid and polyT20-PEG-lipid treated-cells were labeled with PKH red 
and green, respectively (Fig. 6a).  The two kinds of cells were mixed and incubated by 
rotation culture.  Attachment between the two types of cells was observed and gradually 
they were alternatively aligned as shown in Fig. 6b.  Cell aggregates were also observed 
after 3-hour of rotation culture.  In contrast, no attachment was observed between cells 
not treated with oligoDNA-PEG-lipid, even after 3 hours of rotation culture.  These 
results suggest alternative cell alignment can be induced by hybridization of oligoDNA 
at the end of PEG-lipid.  A biotin-PEG-lipid and streptavidin interaction can also be 
used to align cells.  
The control over the attachment between heterogeneous or homogeneous cells 
can be a useful tool in the biomedical research field. The technique should be applied to 
the analysis of cell-cell interaction, the induction of cell fusion, and so on. The analysis 
of cell-cell interaction is important in stem cell research as hope for embryonic stem 
(ES) cells and induced pluripotent stem (iPS) cells has increased over the past few 
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years.
67
 Methods for regulating the cell-cell interaction should be intensively studied 
and developed. Cell-cell interactions should be expanded because they might imitate 
natural embryo development and, thus, are expected to be much more powerful than 
other methods of ES cell differentiation. In addition, cell fusion has been performed by 
the use of concentrated poly(ethylene glycol) (PEG) and electrofusion, however, the 
efficiency of cell fusion should be improved. It would be useful for the formation of 
hybrodoma for production of monoclonal antibodies. Recently it was reported that 
somatic cells could be induced into undifferentiated cells by cell fusion with ES cells.
68
 
The improvement of cell fusion should be contributed to this research field. Thus the 
control of cell-cell attachment could be an important technique. 
 
5. 2. Encapsulation of islets with cells 
We recently attempted to encapsulate islets with living cells.
17
 If the surface of islets 
can be covered with living cells such as vascular endothelial cells or fibroblasts, derived 
from the recipient, biocompatibility is expected to be significantly improved and the 
immune-rejection reaction evaded.  Therefore, we attempted to microencapsulate islets 
with a living cell layer membrane.
17
 To our knowledge, there have been no previous 
reports of microencapsulating islets with living cells.  We used amphiphilic PEG-lipid 
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and the biotin/streptavidin reaction to immobilize HEK293 cells on the surface of islets, 
as shown in Fig. 7a.  After biotin molecules were introduced on the surface of HEK293 
cells by biotin-PEG-lipid, streptavidin was immobilized to the surface.  Then biotin-
PEG-lipid modified islets were mixed with streptavidin-immobilized HEK293 cells.  
HEK293 cells were immobilized on the islet surface (Fig. 7b).  The surface of the islets 
was completely covered with a cell layer after 3 to 5 days in culture without central 
necrosis of the islet cells (Fig. 7c and d).  Insulin secretion was well maintained upon 
glucose stimulation of HEK293 cell-encapsulated islets.  We were successful in 
microencapsulating islets with a cell layer, although HEK293 cells are a cell line.  We 
are trying to microencapsulate islets with human vascular endothelial cells using the 
same technique.  
Islets are exposed to fresh blood when they are transfused into the liver through the 
portal vein. The coagulation and complement systems are activated by the islet surface 
during the early post-transplantation phase, leading to the release of chemotactic factors, 
tissue factor, chemokines, and other inflammatory mediators. The transplanted islets are 
destroyed by the innate immune reactions.
27
 Therefore, the new idea to overcome these 
issues is the encapsulation of islet with endothelial cells to suppress blood-mediated 
inflammatory reactions because the surface of endothelial cells is inert to blood. We 
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believe our technique can be useful to suppress some inflammatory reactions after islet 
transplantation into liver through portal vein in the current clinical protocol. 
 
5. 3. Control lineages of embryonic stem cells by cell-cell interaction 
The attachment of different kinds of cells, including single cells and cell aggregates, can 
be successfully induced by surface modification with PEG-lipid carrying biotin and 
streptavidin or complementary DNA sequences.  With these techniques, we have 
induced intimate cell-cell contact between mouse embryonic stem (ES) cells and feeder 
cells.  The lineage fate of ES cells is thought to be determined by cell-cell interactions 
(H. Iwata et al Biomaterials, submitted).  We analyzed the neuronal differentiation of 
ES cells by immunostaining over time.  We used HEK293 cells (human endoderm 
kidney cell line) and PA6 cells (PA6 cells derived from skull bone marrow) as feeder 
cells.  HEK293 cells, genetically modified to express green fluorescent protein, were 
immobilized on the embryoid body (EB) surface, an aggregate of mouse ES cells.  The 
cells uniformly attached and spread onto the EBs, proliferating to cover the whole 
surface of the EBs (Fig. 8).  PA6 cells (labeled with Cell Tracker Green) initially 
attached uniformly to the EBs; yet, they could not cover the EB surface completely.  
HEK293 and PA6 cells were expected to exert different effects on ES cells in EBs.  The 
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frozen sections of EBs, treated with these two kinds of cells, were analyzed by immuno-
staining against neuron markers, Nestin and TuJ1 (lower panels in Fig. 8).  Anti-Nestin 
and TuJ1 antibodies were used to find neural progenitor cells and mature neurons, 
respectively, in the EBs.  Nestin stained red, TuJ1 stained green, and the nuclei were 
stained with Hoechst blue (Fig. 8).  The ES cells were promoted to differentiate into 
neural cells when PA6 cells were immobilized on the EB surface.  Strong expression of 
Nestin and TuJ1 was found locally at the parts of the EBs where PA6 cells were 
attached.  In contrast, contact interaction with HEK293 cells completely suppressed the 
neuronal differentiation of ES cells.  These results suggest our method, using biotin-
PEG-lipid and streptavidin, is promising for studying the effects of intercellular contact 
interactions on the differentiation of ES cells.  Although the results presented here are 
preliminary, we expect the application of this technology to stem cell research and 
embryology will be of much interest to the area of cell biology. 
 
6. Conclusion and perspective 
The application of cell surface modification to cell transplantation will have a strong 
impact on the therapies of various endocrine diseases.  Its effectiveness has been 
demonstrated using animal models suffering from type I diabetes, as discussed in 
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relation to the bioartificial pancreas.  The same technologies can be applicable to 
disorders of the central nervous system such as Parkinson’s, Alzheimer’s, ALS, and 
Huntington’s disease because it is necessary to prevent the graft loss from the attack by 
immune-rejection reaction.
59-66
 It is also considered that the early graft loss should be 
serious problem which indicates that the most transplanted cells would be lost before 
immune-rejection. As we already mentioned, transplanted cells are destroyed by the 
innate immune reactions which are activated by coagulation and complement systems 
when cells are exposed to fresh blood. Therefore, it is important to modify the cell 
surface with biocompatible polymers, bioactive substances, and living cells derived 
from patients to suppress the graft loss not only from the innate immune reactions but 
also from immune-rejection reaction. Our surface modification methods described here 
can be applied to the all kinds of cells for transplantation and have a potential for 
improvement of graft survival. Also for our conformal coating method, there is no 
volume increase, indicating that the same clinical protocol of transplantation can be 
applied after the surface modification. 
Clinical applications of the technology are mainly restricted by the shortage of cells 
from human donors.  However, various functional cells have been derived from human 
ES cells.  In addition, Yamanaka et al.
 67
 developed a method to obtain induced 
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pluripotent stem (iPS) cells from a patient’s skin cells, which have pluripotency as ES 
cells.  Sufficient numbers of these pluripotent stem cells will be obtained in the near 
future and the technology of cell surface modification will be successfully applied to 
treat human patients. However, for treatment of autoimmune disease such as type I 
diabetes, it is also necessary to suppress the immune reactions although cells were 
obtained from patients because autoimmune disease is to attack autologous cells. For 
this case, it is important to modify the cell surface to suppress the immune reactions. 
Our review is summarized as follows. The cell surface modification methods are 
classified into three categories: (1) covalent conjugation to amino groups of cell surface 
proteins, (2) electrostatic interaction between cationic polymers and a negatively 
charged surface, and (3) incorporation of amphiphilic polymers into the lipid bilayer 
membrane of cells by hydrophobic interaction as summarized in Fig. 2. However, the 
use of cationic polymers is difficult for cell surface modification because they are 
generally cytotoxic to most cells through the method (2). The method (1) and (3) are 
appropriate for cell surface modification due to no cytotoxicity. For these methods, the 
stability of polymers on the cell surface is almost the same. The difference between 
these methods is covalent conjugation to membrane proteins or hydrophobic insertion 
into membrane. It is possible to immobilize bioactive substances to the cell surface and 
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to form layer-by-layer membrane on the surface through these methods. Conformal 
coating of cells for transplantation can be achieved through covalent conjugation or 
hydrophobic interaction. These methods are promising for improvement of graft 
survival. Thus the surface modification by covalent conjugation is useful, however, 
there is a potential for denaturation membrane proteins due to the chemical modification 
of membrane and cytoplasmic proteins. And the potential of functional groups is limited 
because there are no varieties of available hetero-bifunctional cross-linkers. On the 
other hand, there is no chemical modification to membrane proteins and cells for surface 
modification by hydrophobic interaction. And it is easy to introduce various functional 
groups including DNA by using PEG-lipid derivatives because the end group of PEG 
chain is available for chemical modification. Several different types of groups can be 
also introduced to the surface to expand in biomedical application. Cell surface 
modification can be also applied to various biomedical research, such as cell-cell 
interaction analysis, cell arrangement, lineage determination of stem cells, and many 
others as we showed in Fig. 6, 7, and 8. Although there is more work to be completed in 
this new research area, this new technology will allow for future advances in biomedical 
engineering and science. 
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8. Figure Captions 
Figure 1. Cell surface modification with synthetic polymers.  Chemical structure of (a) 
poly(ethylene glycol) (PEG), (b) PEG carrying N-hydroxyl-succinimidyl ester (PEG-
NHS), (c) PEG-conjugated phospholipid (PEG-lipid) and poly(vinyl alcohol) carrying 
side alkyl chains (PVA-alkyl), (d) poly(ethyleneimine) (PEI), and (e) poly(allylamine) 
(PAA), poly(styrene) sulfate (PSS), PVA derivative (PVA-SH, PVA-PD).  (f) 
Schematic illustration of surface modification of a cell with synthetic polymers by 
covalent bonding, hydrophobic interaction, electrostatic interaction, and the layer-by-
layer method.  (g) Schematic illustration of the immobilization of bioactive substances 
to the cell surface via polymers.  
 
Figure 2. Cell surface modification with amphiphilic PEG-lipid.  (a) Chemical structure 
of PEG-lipid derivatives, R is a functional group such as an amino group, biotin, 
maleimide group, or oligo DNA.  Schematic illustration shows the interaction between 
PEG-lipid and the lipid bilayer of a cell membrane.  (b) Real-time monitoring of 
incorporation of PEG-lipid into a supported lipid membrane by a surface plasmon 
resonance (SPR) instrument.  Suspension of a small unilamellar vesicle of egg york 
lecithin (70 g/mL) was applied to a methyl-terminated self-assembly monolayer (CH3-
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SAM) surface.  A PEG-lipid solution (100 µg/mL) was then applied.  Here we used 
three kinds of PEG-lipids with different length acyl chains; PEG-DMPE, PEG-DPPE, 
and PEG-DSPE have 14, 16, and 18 carbons, respectively, in an acyl chain.  (c) 
Observation of FITC-labeled PEG-lipid modified CCRF-CEM cells by a confocal laser 
scanning microscope  The fluorescence of FITC was observed at the periphery of all 
cells, indicating PEG-lipids are anchoring to the lipid bilayer membrane of the cell 
surface by hydrophobic interaction. 
 
Figure 3. Immobilization of urokinase on the surface of islets.  (a) Immobilization of 
urokinase to the islet surface using amphiphilic PVA-alkyl.  (b) Fibrin plate assay of 
urokinase-immobilized islets.  Urokinase-immobilized islets and non-treated islets (100 
islets each) were placed on a fibrin gel plate and incubated at 37 C for 13 h.  A large 
transparent area formed around the urokinase-immobilized islets due to dissolution of 
the fibrin gel by plasmin, which is produced from plasminogen by urokinase.  
 
Figure 4. Bioartificial pancreas.  (a) The concept of an immuno-isolation membrane.  
(b) Enclosure of islets in agarose microcapsules.  
 
 - 42 - 
Figure 5. Photos of surface modification of cells (CCRF-CEM) and enclosure of islets 
with thin polymer membranes via PEG-lipid derivatives, taken by a confocal laser 
scanning microscope.  (a) FITC-PEG-lipid modified CCRF-CEM cells.  (b) FITC-PEG-
lipid modified islets.  (c) Layer-by-layer membrane of PVA-coated islets.  PVA was 
labeled with FITC.  (d) Layer-by-layer membrane of biotin-BSA and FITC-streptavidin-
coated islets.  
 
Figure 6. Alignment of single cells by interactions between complementary oligoT and 
oligoA, introduced on different cell surfaces.  (a) Chemical structure of oligoDNA-
PEG-lipid and oligoDNA sequences (polyA20 and polyT20).  (b) Alignment of single 
cells.  PolyA20 and polyT20 cells are labeled with PKH red and PKH green, 
respectively.  The cell attachment was induced by hybridization between polyA20 and 
polyT20 attached to PEG-lipid on the cell surface. 
 
Figure 7. Encapsulation of islets with living cells.  (a) Schematic illustration depicting 
how to enclose an islet with living cells utilizing the avidin and biotin interaction.  (b) 
Hamster islets modified with biotin-PEG-lipid were immobilized with streptavidin-
immobilized HEK293 cells.  HEK293 cells were labeled with CellTracker®.  (c) Phase 
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contrast microscopic images of islets carrying HEK293 cells and histochemical analyses 
(HE staining and immunostaining) of HEK293 cells-immobilized islets in culture.  (c)-
lower right; Alexa 488-labeled anti-insulin antibody and Hoechst 33342 dye for nuclear 
staining.  The pictures are merged images from insulin and Hoechst 33342 staining.  (d) 
GFP-expressing HEK293 encapsulated islets observed at 3 days culture and their sliced 
section at 3 days. 
 
Figure 8. Immunocytochemical analyses of EBs carrying GFP-HEK293 and PA6 cells 
after 6 days of hanging drop culture.  Untreated EBs were used as controls.  GFP-HEK 
and PA6 cells labeled with PKH67 (green) were used.  Upper panels show the confocal 
laser scanning images.  Frozen sample sections (lower panels) were stained with 
antibodies for Nestin (red) and TuJ1 (green), which are markers of neural progenitor 
cells and mature neurons, respectively.  Hoechst 33342 dye (blue) was used for nuclear 
staining.  The pictures are merged images from Nestin, TuJ1, and Hoechst 33342 
staining.  The arrows indicate the local expression of Nestin and TuJ1.   
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